UnicoCell Biomed Co., Ltd. (TPE:6794)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
62.50
+0.50 (0.81%)
Jul 22, 2025, 1:03 PM CST
-23.22%
Market Cap3.79B
Revenue (ttm)39.06M
Net Income (ttm)-89.90M
Shares Out60.68M
EPS (ttm)-1.54
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,000
Average Volume14,219
Open62.80
Previous Close62.00
Day's Range61.20 - 62.80
52-Week Range60.80 - 83.00
Beta-0.35
RSI48.29
Earnings DateAug 8, 2025

About UnicoCell Biomed

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs, cell therapy technology, and regenerative medical services in Taiwan. It develops ELIXCYTE, which is in Phase 2 clinical trials for the treatment of osteoarthritis and chronic kidney disease. The company offers UnicoVial, a cryotube and drug container for cell therapy products, as well as provides testing services. UnicoCell Biomed Co., Ltd. is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Yi-Pei Hung
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6794
Full Company Profile

Financial Performance

In 2024, UnicoCell Biomed's revenue was 31.88 million, an increase of 29.66% compared to the previous year's 24.59 million. Losses were -93.07 million, 10.7% more than in 2023.

Financial Statements

News

There is no news available yet.